Literature DB >> 10579665

Cognitive outcome after emergent treatment of acute herpes simplex encephalitis with acyclovir.

C P Kaplan1, K P Bain.   

Abstract

Longitudinally designed case studies, reporting cognitive and psychosocial outcome of herpes simplex virus encephalitis (HSVE), were conducted prior to current antiviral medication usage and primarily in persons with either left hemispheric or bilateral temporal lobe involvement. The current study demonstrated relatively better outcome (cognitive recovery and functional independence for activities of daily life) in an individual treated with IV Acyclovir within hours of initial symptoms and whose CT scans showed right hemispheric involvement. In contrast with earlier case reports, no semantic specific categories of memory impairment were noted on serial assessment. The time from first symptoms to antiviral medical treatment appears to be the best predictor of outcome from HSVE. Historical case studies with relatively poorer outcome and differing deficits suggest survivors of HSVE are a heterogenous group. Variability in anatomic lesions and time to treatment contribute to outcome.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10579665     DOI: 10.1080/026990599121133

Source DB:  PubMed          Journal:  Brain Inj        ISSN: 0269-9052            Impact factor:   2.311


  3 in total

1.  Dementia following herpes zoster encephalitis.

Authors:  Katherine J Bangen; Lisa Delano-Wood; Christina E Wierenga; Nikki H Stricker; John R Hesselink; Mark W Bondi
Journal:  Clin Neuropsychol       Date:  2010-05-24       Impact factor: 3.535

2.  Results of a multinational study suggest the need for rapid diagnosis and early antiviral treatment at the onset of herpetic meningoencephalitis.

Authors:  Hakan Erdem; Yasemin Cag; Derya Ozturk-Engin; Sylviane Defres; Selcuk Kaya; Lykke Larsen; Mario Poljak; Bruno Barsic; Xavier Argemi; Signe Maj Sørensen; Anne Lisbeth Bohr; Pierre Tattevin; Jesper Damsgaard Gunst; Lenka Baštáková; Matjaž Jereb; Isik Somuncu Johansen; Oguz Karabay; Abdullah Umut Pekok; Oguz Resat Sipahi; Mahtab Chehri; Guillaume Beraud; Ghaydaa Shehata; Rosa Fontana Del Vecchio; Mauro Maresca; Hasan Karsen; Gonul Sengoz; Mustafa Sunbul; Gulden Yilmaz; Hava Yilmaz; Ahmad Sharif-Yakan; Souha Shararah Kanj; Emine Parlak; Filiz Pehlivanoglu; Fatime Korkmaz; Suheyla Komur; Sukran Kose; Mehmet Ulug; Sibel Bolukcu; Seher Ayten Coskuner; Nevin Ince; Yasemin Akkoyunlu; Gulistan Halac; Elif Sahin-Horasan; Hulya Tireli; Gamze Kilicoglu; Akram Al-Mahdawi; Salih Atakan Nemli; Asuman Inan; Seniha Senbayrak; Jean Paul Stahl; Haluk Vahaboglu
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

3.  Application of real-time PCR for testing antiviral compounds against Lassa virus, SARS coronavirus and Ebola virus in vitro.

Authors:  Stephan Günther; Marcel Asper; Christina Röser; Luciano K S Luna; Christian Drosten; Beate Becker-Ziaja; Peter Borowski; Huan-Ming Chen; Ramachandra S Hosmane
Journal:  Antiviral Res       Date:  2004-09       Impact factor: 5.970

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.